According to our (Global Info Research) latest study, the global Empagliflozin and Metformin Hydrochloride Tablets market size was valued at US$ 121 million in 2025 and is forecast to a readjusted size of US$ 539 million by 2032 with a CAGR of 15.3% during review period.
In 2025, global Empagliflozin and Metformin Hydrochloride Tablets production reached approximately 830 million units.Empagliflozin and Metformin Hydrochloride Tablets are a combination oral antidiabetic medication composed of the SGLT2 inhibitor empagliflozin and the biguanide agent metformin. The drug exerts its glucose-lowering effect through a dual mechanism: on one hand, empagliflozin reduces blood glucose levels by inhibiting renal glucose reabsorption and promoting urinary glucose excretion; on the other hand, metformin lowers blood glucose primarily by suppressing hepatic glucose production and improving insulin sensitivity. The combination provides a synergistic effect in glycemic control, while also offering benefits in weight management and cardiovascular outcomes. It is widely used for the management of patients with type 2 diabetes mellitus, particularly those with inadequate control on monotherapy.
Empagliflozin and Metformin Hydrochloride Tablets, as a fixed-dose combination (FDC) of an SGLT2 inhibitor and a biguanide, are positioned within the rapidly growing oral antidiabetic drug market. With the global prevalence of type 2 diabetes continuing to rise and increasing demand for the management of cardiovascular and renal complications, therapies that offer both glycemic control and cardiorenal benefits are gaining significant attention. This product achieves synergistic glucose-lowering through a dual mechanism and offers advantages such as oral administration and improved patient compliance, gradually replacing some monotherapy or more complex combination regimens in clinical practice. Meanwhile, the growing recommendation of SGLT2 inhibitors in international guidelines is further driving market penetration. In mature markets, such combination products have become important therapeutic options, while in emerging markets, expanding insurance coverage and improved accessibility are unlocking substantial growth potential. Overall, the product is expected to maintain steady growth under the long-term trends of diabetes management and comprehensive chronic disease care.
This report is a detailed and comprehensive analysis for global Empagliflozin and Metformin Hydrochloride Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Empagliflozin and Metformin Hydrochloride Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Empagliflozin and Metformin Hydrochloride Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Empagliflozin and Metformin Hydrochloride Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Empagliflozin and Metformin Hydrochloride Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Empagliflozin and Metformin Hydrochloride Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Empagliflozin and Metformin Hydrochloride Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim, Eli Lilly and Company, Lupin Limited, Kureasia Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Empagliflozin and Metformin Hydrochloride Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Immediate-release (IR)
Sustained-release (SR)
Market segment by Dosage Form
Tablets
Powder
Market segment by Production Technology
Innovator Drug
Generic Drug
Market segment by Application
Type 2 Diabetes Mellitus
Cardiovascular
Renal Protection
Others
Major players covered
Boehringer Ingelheim
Eli Lilly and Company
Lupin Limited
Kureasia Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Empagliflozin and Metformin Hydrochloride Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Empagliflozin and Metformin Hydrochloride Tablets, with price, sales quantity, revenue, and global market share of Empagliflozin and Metformin Hydrochloride Tablets from 2021 to 2026.
Chapter 3, the Empagliflozin and Metformin Hydrochloride Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Empagliflozin and Metformin Hydrochloride Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Empagliflozin and Metformin Hydrochloride Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Empagliflozin and Metformin Hydrochloride Tablets.
Chapter 14 and 15, to describe Empagliflozin and Metformin Hydrochloride Tablets sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Empagliflozin and Metformin Hydrochloride Tablets. Industry analysis & Market Report on Empagliflozin and Metformin Hydrochloride Tablets is a syndicated market report, published as Global Empagliflozin and Metformin Hydrochloride Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Empagliflozin and Metformin Hydrochloride Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.